Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.57 |
| ▸ | GSK3B | P49841 | 11/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9753841 | 0.81 | EPHX2 (0.43) | EPHX2KCNQ3KCNQ2P4HA1P4HTM | |
| SCHEMBL9670852 | 0.81 | GSK3B (0.48) | GSK3BEPHX2KCNQ3KCNQ2 | |
| SCHEMBL5327128 | 0.81 | MAPT (0.44) | EPHX2KCNQ3KCNQ2 | |
| SCHEMBL934394 | 0.78 | GSK3B (0.55) | PTPN1GSK3BP4HA1P4HTM | |
| SCHEMBL16601153 | 0.78 | PTPN1 (0.55) | PTPN1GSK3BP4HA1P4HTM | |
| SCHEMBL18921446 | 0.78 | EPHX2 (0.41) | EPHX2KCNQ3KCNQ2 | |
| SCHEMBL27594193 | 0.77 | RXFP1 (0.53) | EPHX2KCNQ3KCNQ2P4HA1P4HTM | |
| SCHEMBL4598633 | 0.77 | GABRP (0.60) | PTPN1GSK3BEPHX2 | |
| Bromide SCHEMBL6118518 | 0.77 | GSK3B (0.53) | PTPN1GSK3BP4HA1P4HTM | |
| SCHEMBL30213417 | 0.77 | GABRP (0.60) | PTPN1GSK3BEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0244728-B1 | USE OF HETEROARYLETHYL AMINES TO STIMULATE ANIMAL GROWTH, HETEROARYLETHYL AMINES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1992-11-11 | — | — | EP | claimed |
| US-7932277-B2 | Peptide inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2185524-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2008141227-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-0244728-B1 | USE OF HETEROARYLETHYL AMINES TO STIMULATE ANIMAL GROWTH, HETEROARYLETHYL AMINES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1992-11-11 | — | — | EP | disclosed |
| US-4816457-A | HYPOTENSIVE AGENTS, BRONCHODILATORS, EYES | MERCK & CO., INC., A CORP. OF NJ | 1989-03-28 | — | — | US | disclosed |
| EP-0105053-B1 | ARALKYLAMINOETHANOL HETEROCYCLIC COMPOUNDS | MERCK & CO. INC. (US) | 1988-01-20 | — | — | EP | disclosed |
| US-4686222-A | ADRENERGIC BLOCKERS, BRONCHODILATORS | MERCK & CO., INC. (US) | 1987-08-11 | — | — | US | disclosed |
| US-4568679-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE AGENTS, BRONCHODILATOR AGENTS, REDUCING INTRAOCULAR PRESSURE | MERCK & CO., INC. (US) | 1986-02-04 | — | — | US | disclosed |
| EP-0105053-A1 | Aralkylaminoethanol heterocyclic compounds | MERCK & CO. INC. (US) | 1984-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, HDGF, EIF2AK2 | PTPN1 2353/4885GSK3B 3028/4885EPHX2 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.